Floatz logo

Palonosetron

Hematopoietic And Lymphoid System Neoplasm

Alliance for Clinical Trials in OncologySmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

134 Active assets in the Hematopoietic And Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
OHSU Knight Cancer Institute
Phase 4BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Dexasone
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Palonosetron is also rated in:

chemotherapy-induced toxicityActive
A
Indicative · Phase 4
82 / 100
View asset →
cancer of unknown primary siteDormant
BB
Indicative · Phase 3
69 / 100
View asset →
lymphomaDormant
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →